Pulmonary Cell News Volume 8.29 | Aug 1 2019

TOP STORY

Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma

Investigators found that mouse LSL –Kras ^G12D; Trp53 ^fl/fl-mediated lung adenocarcinoma tumorigenesis could proceed through both PKCι-dependent and PKCι-independent pathways. [Cancer Cell] Abstract | Graphical Abstract | Press Release

(Ranked by impact factor of the journal)

Mitofusins Regulate Lipid Metabolism to Mediate the Development of Lung Fibrosis

Scientists report that the absence of the mitochondrial fusion proteins mitofusin 1 and mitofusin 2 in murine AEC2 cells led to morbidity and mortality associated with spontaneous lung fibrosis. [Nat Commun] Full Article

The Role of miR-200b-3p in Modulating TGF-β1 Induced Injury in Human Bronchial Epithelial Cells

miR-200b-3p was downregulated post TGF-β1 treatment compared to control in BEAS-2B. miR-200b-3p mimicked transfection prior to TGF-β1 stimulation maintained epithelial marker expression and downregulated mesenchymal cell markers at RNA and protein level in BEAS-2B cells and primary bronchial epithelial cells. [Transplantation] Abstract | Full Article Download

In Vitro Antibacterial Activity of Ciprofloxacin Loaded Chitosan Microparticles and Their Effects on Human Lung Epithelial Cells

The authors report on the preparation and in vitro antibacterial activity and cytotoxicity determination of ciprofloxacin loaded chitosan microparticles with size in the range of 0.1-1 µm, which may provide advantages of lower nanotoxicity and lower local clearance. The biocompatibility of the microparticles was tested in the human lung epithelial cell culture, and microparticle association with the bacteria and epithelial cells was evaluated by transmission electron microscopy. [Int J Pharm] Abstract | Graphical Abstract

LUNG CANCER

MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Treatment with MEK inhibitors (MEKi) led to acquisition of a novel vulnerability to TNFa and IFNg-induced apoptosis in lung cancer cells that were refractory to MEKi killing and augmented cell cycle arrest. Abolishing the expression of TNFR1 on lung cancer cells impaired the anti-tumor efficacy of MEKi while the administration of TNFa and IFNg in MEKi-treated mice enhanced the anti-tumor response. [Cancer Res] Abstract

Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival

Overexpression of aldolase A increased migration and invasion of lung cancer cell lines in vitro and formation of metastatic lung cancer foci in vivo. [Cancer Res] Abstract

RBM47-Regulated Alternative Splicing of TJP1 Promotes Actin Stress Fiber Assembly during Epithelial-to-Mesenchymal Transition

The authors showed that an isoform of tight junction protein 1 (TJP1) lacking exon 20 was predominantly expressed in tumor tissues and in A549 cells during transforming growth factor-β-induced epithelial-mesenchymal transition. [Oncogene] Abstract

LncRNA TTN-AS1 Promotes Migration, Invasion, and Epithelial Mesenchymal Transition of Lung Adenocarcinoma via Sponging miR-142-5p to Regulate CDK5

Knockdown of titin-antisense RNA1 (TTN-AS1) significantly inhibited the growth, proliferation, migration, and invasion ability of lung adenocarcinoma cells in vitro. [Cell Death Dis] Full Article

Neutralizing Monoclonal Antibody against Dickkopf2 Impairs Lung Cancer Progression via Activating NK Cells

Researchers found significant upregulation of Dickkopf-related protein 2 (DKK2) expression in adenomatous polyposis coli-mutated lung cancers. Administration of DKK2 antibody inhibited cancer growth via modulating tumor immune microenvironment in lung cancer mouse models. [Cell Death Discov] Full Article

Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News.

The Biological Functions and Clinical Applications of Exosomes in Lung Cancer

Scientists discuss the roles of exosomes in a lung cancer microenvironment, such as its participation in lung cancer initiation, progression and metastasis as well as being involved in angiogenesis, epithelial-mesenchymal transition, immune escape, and drug resistance. [Cell Mol Life Sci] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients

Arcturus Therapeutics announced that the Cystic Fibrosis Foundation has increased its commitment to $15 million in conjunction with an amended agreement to advance LUNAR-CF, a novel mRNA therapeutic formulated with Arcturus’ LUNAR^® delivery technology. [Arcturus Therapeutics Holdings Inc. (GlobeNewswire, Inc.)] Press Release

Lotus Pharmaceutical Launched Vinorelbine Softgel Capsule, a Generic Navelbine^®, in European Markets as the First Generic

Lotus Pharmaceutical Co., Ltd confirmed the launch of Vinorelbine 20, 30 and 80mg soft capsules in Europe. The product is a generic alternative of Pierre Fabre Médicament’s Navelbine^® indicated for treatment of advanced non-small-cell lung cancer and advanced breast cancer when other treatment is not appropriate. [Lotus Pharmaceutical Co., Ltd] Press Release

Eloxx Pharmaceuticals Announces Open Investigational New Drug Application (IND) for a Phase II Clinical Trial of ELX-02 in Cystic Fibrosis Patients with the G542X Mutation in the US and Protocol Endorsement from the Cystic Fibrosis Foundation (CFF)

Eloxx Pharmaceuticals, Inc. announced that an IND for ELX-02 in CF is now open in the US and the Phase II clinical trial has been endorsed by the CFF. [Eloxx Pharmaceuticals, Inc.] Press Release

Roche Receives CHMP Positive Opinion for New Tecentriq-Based Combination Therapy as an Initial Treatment for Most Common Form of Advanced Lung Cancer

Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq^® in combination with chemotherapy, for the initial treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC. [F. Hoffmann-La Roche Ltd.] Press Release

Did CRISPR Help—or Harm—the First-Ever Gene-Edited Babies?

Since the gene-edited babies known as Lulu and Nana became international news in November 2018, scientific debate and media speculation have swirled around the potential impacts of modifying their gene for CCR5. [ScienceInsider] Editorial

‘No One Is Immune’: Alaska’s Scientists Despair over Plan to Shrink State Universities

The University of Alaska’s governing board plans to consolidate campuses to cope with a 40% cut in state funding. [Nature News] Editorial

Survey of Stem Cell Clinics Reveals Cause for Concern

Two co-authors of a new study discuss their findings about nearly 170 facilities in the southwestern US selling unproven therapies—and what should be done about them. [The Scientist] Editorial

NEW 2019 National Cancer Research Institute Cancer Conference
November 3-5, 2019
Glasgow, United Kingdom

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Research Fellow – Lung Cancer Immunology (Memorial Sloan Kettering Cancer Center)

Scientific Communications Coordinator (STEMCELL Technologies Inc.)

Scientist – Pulmonary (STEMCELL Technologies Inc.)

Assistant/Associate Professor – Respiratory Tract Infections (Hannover Medical School)

Postdoctoral Fellowship – Lung Epithelium (Boston University)

Postdoctoral Positions – Pulmonary Injury (University of Maryland)

PhD Studentship – Extracellular Vesicles in Pulmonary Fibrosis (Université de Franche-Comté)

Postdoctoral Position – Lung Injury (University of Connecticut)

Postdoctoral Fellowship – Redox Biology of Lung and Breast Cancer (Washington University School of Medicine)

Postdoctoral Fellow – Pluripotent Stem Cell-Derived Human Lung Organoids (Columbia University Irving Medical Center)

Postdoctoral Researcher – Lung Lineage Development (Hospital for Sick Children)

Assistant Professor – Lung Disease Research (University of McGill)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.